Comparing antigenaemia - and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa
Published: 30 September 2022| Version 1 | DOI: 10.48765/nxq0-6562
Contributors:
, , , , , , , , , , , , , , Description
Data collected from participants at four separate timepoints in Cote d'Ivoire and Liberia identified by a unique participant ID. There are four timepoints collected from each country: Baseline, Follow-up Year 1, Follow-Up Year 2, and Follow-up Year 3. Each dataset includes the participant ID, gender, age, the microfilarae (MF) count collected through blood smear, and circulating filarial antigen (CFA) result from a strip test.
Files
Institutions
Erasmus Universiteit Rotterdam, University of Surrey, University of Oxford, Washington University in St. Louis, University of Notre Dame, University of Birmingham, Centre Suisse de Recherches Scientifiques en Cote d'Ivoire, University of South Florida
Categories
Medicine, Health Sciences, Parasitic Disease, Disease Modeling
Funding
Bill and Melinda Gates Foundation
OPPGH5342
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
016.Veni.178.023
Bill and Melinda Gates Foundation
OPP1184344
Additional Metadata for Digital Commons Data@Becker
| Keywords | Lymphatic Filariasis, Elimination, Mass Drug Administration, Mathematical Modelling, Albendazole, Endpoints, Ivermectin |
| Other Contributing Institutions | National Public Health Institute of Liberia, Ministry of Health and Social Welfare of Cote d'Ivoire |